Free Trial
NASDAQ:TLSI

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$2.28 -0.15 (-6.17%)
Closing price 03:59 PM Eastern
Extended Trading
$2.27 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Advanced

Key Stats

Today's Range
$2.17
▼
$2.57
50-Day Range
$2.30
▼
$5.10
52-Week Range
$2.17
▼
$7.95
Volume
389,909 shs
Average Volume
300,557 shs
Market Capitalization
$140.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.20
Consensus Rating
Moderate Buy

Company Overview

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion.

The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

TriSalus became publicly traded following its 2023 business combination with MedTech Acquisition Corporation. The company is headquartered in Westminster, Colorado.

AI Generated. May Contain Errors.

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

TLSI MarketRank™: 
3.026786898285 of 5 stars

TriSalus Life Sciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 370th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    TriSalus Life Sciences has a consensus price target of $9.20, representing about 317.2% upside from its current price of $2.21.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.62) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.43% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 28.45, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently decreased by 3.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • News Sentiment

    TriSalus Life Sciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for TriSalus Life Sciences this week, compared to 3 articles on an average week.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $109,274.00 in company stock, which represents 0.0805% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have bought 4,008.58% more of their company's stock than they have sold. Specifically, they have bought $112,000.00 in company stock and sold $2,726.00 in company stock.

  • Percentage Held by Insiders

    16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLSI Stock News Headlines

What is HC Wainwright's Estimate for TLSI FY2026 Earnings?
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
TriSalus (TLSI) Q3 2026 Earnings Call Transcript
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $6.98 at the beginning of 2026. Since then, TLSI shares have decreased by 68.4% and is now trading at $2.2050.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million.
Read the conference call transcript
.

Top institutional shareholders of TriSalus Life Sciences include State Street Corp (1.09%), Nantahala Capital Management LLC (0.81%), White Pine Capital LLC (0.81%) and Royce & Associates LP (0.32%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Mats Wahlstrom, Sean Murphy, Bryan F Cox, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young.
View institutional ownership trends
.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include Definium Therapeutics (DFTX), Palantir Technologies (PLTR), Solid Biosciences (SLDB), Cabaletta Bio (CABA), Biomea Fusion (BMEA), Amprius Technologies (AMPX) and Cameco (CCJ).

Company Calendar

Last Earnings
11/10/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
CIK
1826667
Fax
N/A
Employees
102
Year Founded
2009

Price Target and Rating

High Price Target
$12.00
Low Price Target
$4.00
Potential Upside/Downside
+303.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.23 million
Net Margins
-56.60%
Pretax Margin
-56.57%
Return on Equity
N/A
Return on Assets
-55.00%

Debt

Debt-to-Equity Ratio
47.60
Current Ratio
4.22
Quick Ratio
3.86

Sales & Book Value

Annual Sales
$46.39 million
Price / Sales
3.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.68) per share
Price / Book
-3.35

Miscellaneous

Outstanding Shares
61,575,000
Free Float
51,538,000
Market Cap
$140.39 million
Optionable
Optionable
Beta
0.50

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners